Previous 10 | Next 10 |
BOSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of William (Bill) H. Carson, M....
BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of leading experts in gene thera...
BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Offic...
Decibel Therapeutics (DBTX): Q1 net loss of $10.87MAs of March 31, 2021, cash, cash equivalents and available-for-sale securities were $191.1 million, compared to $54.3 million as of December 31, 2020. The increase in cash, cash equivalents and available-for-sale securities was due to the sal...
– Established cGMP manufacturing and development agreement with Catalent for otoferlin dual-vector gene therapy, DB-OTO – – Successfully completed the second tranche of an oversubscribed Series D financing and upsized Initial Public Offering raising app...
BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present two digital presentations...
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Off...
Gainers: [[CAN]] +8.6%. [[NLOK]] +8.3%. [[QK]] +8.1%. [[QTRX]] +5.2%. [[DBTX]] +4.5%.Losers: [[KELYB]] -7.8%. [[PFIN]] -4.7%. [[OVID]] -3.7%. [[HPK]] -3.2%. [[RMNI]] -2.3%. For further details see: QTRX, QK, PFIN and OVID among after-hours movers
Decibel Therapeutics (DBTX): FY Net loss $39.34MAs of December 31, 2020, cash, cash equivalents and available-for-sale securities were $54.3M.Press Release For further details see: Decibel Therapeutics reports FY results
-Successfully completed an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $220.1M in gross proceeds- -Established development and manufacturing agreement for otoferlin dual-vector gene therapy with Catalent- -Launched Amplify&...
News, Short Squeeze, Breakout and More Instantly...
Decibel Therapeutics Inc. Company Name:
DBTX Stock Symbol:
NASDAQ Market:
Decibel Therapeutics Inc. Website:
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Decibel Therapeutics Inc. (DBTX) is expected to report $-0.61 for Q3 2023
NEW YORK, NY / ACCESSWIRE / August 15, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Decibel Therapeutics, Inc. (NASDAQ:...